Eisai’s Leqembi Pen approved in Japan for weekly Alzheimer’s treatment
AI Summary- Eisai received Japanese approval for Leqembi Pen as a subcutaneous treatment route for early Alzheimer’s disease.
- Leqembi Pen uses two weekly injections totaling 500 milligrams, with each injection taking about 15 seconds.
- Japan became the third country globally to approve Leqembi’s subcutaneous formulation.